📰 What This Document Is 📜

This filing is a Form 6-K, which is a report used by foreign private issuers—companies that list shares in the U.S. but are headquartered elsewhere—to provide updates on material events. Since Novo Nordisk is a Danish company, the 6-K acts like a formal announcement to U.S. investors.

The key takeaway is that this report is specifically designed to update the market on the company's ongoing share repurchase program, detailing the progress and the current share ownership figures.

👉 In short, Novo Nordisk is letting the public know how much cash it has spent recently to buy back its own stock.

🏢 What Novo Nordisk Does 💉

Novo Nordisk is a major global healthcare company with deep roots in medicine. Founded back in 1923 and headquartered in Denmark, its entire purpose revolves around fighting severe chronic diseases, starting with its history in diabetes treatment.

The company achieves this by pioneering new scientific breakthroughs and expanding access to its medications worldwide. They operate on a vast scale, employing about 68,800 people and marketing their products in roughly 170 countries.

👉 This scale signals that Novo Nordisk is a massive, established player in the global life sciences and pharmaceutical market.

💰 Total Share Buyback Program Scope 🎯

Novo Nordisk announced a large, long-term program to repurchase its own stock (B shares). This strategy is a way for a company to give back value to shareholders and reduce the number of shares available on the open market.

The company began this overall effort on February 4, 2026, and has set a very large ceiling for the total program. The maximum amount Novo Nordisk expects to spend is up to DKK 15 billion.

👉 This comprehensive, 12-month buyback program shows management's intent to use capital to support its stock price and return value to shareholders.

📊 Current Repurchase Metrics and Progress 📈

The repurchase program is broken into smaller, more manageable periods. Novo Nordisk initially set a goal for the period between February 4, 2026, and May 4, 2026.

During this specific period, the company planned to repurchase B shares for an amount up to DKK 3.8 billion. The reporting details the accumulation of purchases made since the last announcement date (April 13, 2026).

👉 The ongoing tracking of spending shows investors exactly how much of the overall DKK 15 billion goal they have realized so far.

💸 Recent Buying Activity Breakdown 🗓️

The filing provides a detailed transaction table, showing the purchases made between April 13, 2026, and April 17, 2026. This data confirms the continuous, active nature of the share buybacks.

Across the listed transactions, the company bought shares over several days, with the total accumulated shares reaching 12,257,992 B shares. The total value of all purchases recorded up to the latest date was DKK 3,148,710,807.

• Accumulated Shares: Since the last announcement, 12,257,992 B shares have been repurchased.
• Average Price: The average purchase price across all these accumulated shares was DKK 256.87 per B share.

👉 This continuous stream of purchases suggests that the buyback program is progressing steadily and actively.

💼 Current Share Ownership and Treasury Stock 🏷️

When a company buys back its own stock, those shares become "treasury shares"—they are held by the company rather than circulating among the public. The filing updates the total outstanding shares and the treasury stock count.

As of April 17, 2026, Novo Nordisk holds 28,397,791 B shares as treasury shares. These shares represent 0.6% of the company's total share capital. The total outstanding shares (A and B) across the company amount to 4,465,000,000 shares.

👉 The rise in treasury shares means that the company is reducing the float (the amount of stock available for public trading), which can be viewed positively by investors.

📞 Key Contacts and Resources 📧

The filing concluded with extensive contact information, which is useful for journalists and financial analysts who want to dig deeper into the company’s operations.

• Media Contacts: Ambre James-Brown (+45 3079 9289) and Liz Skrbkova (US) (+1 609 917 0632) handle press inquiries.
• Investor Relations Contacts: Dedicated contacts are listed for both Denmark and the US, making it clear who to speak with regarding stock or financial questions.

👉 These blocks ensure that any external party knows exactly who to call or email for specific information.

🧑‍💼 Official Sign-Off ✍️

The report was officially signed by Novo Nordisk's Chief Executive Officer, Maziar Mike Doustdar. The date of the official filing is April 20, 2026.

This formal signature confirms that the information provided in the 6-K is officially disclosed by the company on that specific date.

---

🧠 The Analogy 🏰

Think of a company's shares like a giant, expensive antique vase. When Novo Nordisk buys back shares, they are essentially taking a chunk of that vase and putting it safely in their own museum collection (the treasury). By removing shares from circulation, they are making the remaining, available vase (the public float) look more valuable and rarer, which often drives up the perceived worth of the whole item.

🧩 Final Takeaway 🌟

Novo Nordisk is executing a large, multi-year strategy to reduce its outstanding share count by repurchasing stock. The company confirms it has actively used over DKK 3.1 billion to date, demonstrating a committed effort to return value and strengthen shareholder interest.